Prospective Surveillance Drug and HDS-Induced Liver Injury

点击翻译按钮获取中文摘要

DESCRIPTION (provided by applicant): The Drug Induced Liver Injury Network (DILIN), funded by the National Institutes of Health, represents a critical strategy to mitigate the adverse consequences of DILI. Already, this extensive network of centers around the U.S. has cultivated an impressive repertoire of case based clinical information and samples which has given important insights into DILI in the U.S. Some of the salient findings that have shaped our understanding of DILI and impact future research plans include the observation that antibiotics are the most common class of agents implicated in DILI, followed by Herbal and Dietary Supplements (HDS). The specific aims of this o Application are as follows: 1) To accrue early DILI cases, and collect serum, tissue, and clinical information on those patients meeting entry criteria through three mechanisms: Gastroenterologist- based; electronic health record (EHR); and population-based surveillance; 2) To continue to administer the DILIN Repository for Herbal and Dietary Supplements (HDS) and facilitate collaborative descriptive and product analysis and genetics research to identify injurious agents and host factors responsible for HDS induced liver injury (HILI); 3) To lead DILIN's effort in the causality assessment process for HILI, including it validation, and contribute to its incorporation into a computer-based instrument that is practical for clinicians and applicable for assessment of injury due to both drugs and HDS; 4) To contribute to the expansion of the Herbal and Dietary Supplement component of LiverTox and facilitate the use of LiverTox as a mechanism for DILI reporting by the medical community at large. To accomplish these aims, key collaborations have been built. Informatics specialists will assist in the design, implementation, validation, and refinement of an electronic health record algorithm. Collaborations have also been built with geneticists and the FDA toxicology group to explore the mechanisms for idiosyncratic liver injury from HDS, as well as to identify the agents responsible for injury. Our research will further refine causality assessment, particularly as it pertains to HILI. Finally, the proposed work will expand the functionality of LiverTox, both as a resource for the clinician and clinical scientist, as well as the individual seeking to report a cae of DILI or HILI.